Charles Bankhead is a staff writer for MedPage Today, a leading source of medical news. With a focus on healthcare and medicine, Charles covers a wide range of topics including emerging treatments, clinical challenges, FDA approvals, and advancements in various medical fields. His work has also been featured in Knowledia.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Charles Bankhead's focus is primarily on medical research, clinical trials, FDA approvals, and scientific developments in healthcare and pharmaceuticals. His coverage includes citing data from various studies and press releases.
If you are reaching out to Charles, consider providing insights or commentary based on recent medical research findings or clinical trial outcomes. Expert opinions related to FDA approvals, drug therapies, or challenges in specific areas of healthcare could be well-received by him.
Since his geographic focus is not specified but his topics are broad and universal, pitches can come from experts across the globe who have valuable insights into these areas of medical research and pharmaceuticals.
This information evolves through artificial intelligence and human feedback. Improve this profile .
— Drug targeting junctional zone reduces GA growth by 48% in 3 months, oral agent moderately active
Office procedure reduced visual field loss by 29% over 6 years versus eye drops
By: Charles
Significant improvement beyond 100 weeks after single injection of mutation-agnostic MCO-010
By: Charles Bankhead
— Provision in drug act would prohibit repackaging Avastin, add millions to anti-VEGF therapy cost
By: Charles Bankhead
— Fewer cancers, cancer deaths prevented; higher cost per quality-year saved
By: Charles Bankhead
— Large cohort study showed cancer risk increased with exposure to fine particulate matter
— A look back at some of the newsworthy developments of 2024 The top stories in non-small cell lung cancer (NSCLC) for 2024 included
By: Charles Bankhead
— News, features, and commentary about cancer-related issues The debate continues over whether some prostate cancers opens in a new tab or window should be called "cancer." ( University of California San Francisco
August 1, 2009 | Dermatology Author and Disclosure Information
— Momentum grows for earlier intervention, including pre-fibrotic disease
(833) 317-6278 
